Lotus Pharmaceutical (1795.TW) Earnings Analysis
Lotus Pharmaceutical (1795.TW) next reports earnings on 2026-08-06, consensus EPS 3.45 TWD. Last quarter (2026-05-11) it missed with EPS 2.18 TWD vs 2.47 TWD est (-11.7%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E 12.75.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 1795.TW next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | 3.45 TWD |
| Revenue estimate | 8.85B |
1795.TW earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | 2.18 TWD | 2.47 TWD | -11.7% | Miss |
| 2026-03-12 | 4.31 TWD | 5.26 TWD | -18.1% | Miss |
| 2025-11-14 | 5.54 TWD | 4.37 TWD | +26.8% | Beat |
| 2025-08-11 | 2.79 TWD | 4.5 TWD | -38% | Miss |
| 2025-05-09 | 5.44 TWD | 4.27 TWD | +27.4% | Beat |
| 2025-03-06 | 4.32 TWD | 3.34 TWD | +29.3% | Beat |
Beat rate: 3/6 (50%) over reported quarters with consensus data.
1795.TW valuation and analyst view
| Trailing P/E | 12.75 |
|---|---|
| Trailing EPS | 14.821 TWD |
| Price / book | 2.04 |
| Dividend yield | 3.07% |
| Market cap | 50.59B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Lotus Pharmaceutical (1795.TW)'s next earnings date?
Lotus Pharmaceutical is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 3.45 TWD and revenue estimate of 8.85B.
Did 1795.TW beat earnings last quarter?
In its 2026-05-11 report, 1795.TW posted EPS of 2.18 TWD versus a 2.47 TWD estimate — a miss of 11.7%.
What is 1795.TW's earnings track record?
Over the last 6 reported quarters with consensus data, 1795.TW beat estimates 3 times (50%).
What is 1795.TW's current P/E ratio and EPS?
1795.TW trades at a trailing P/E of 12.75 on trailing EPS of 14.820632098993444 TWD.
What do analysts rate 1795.TW?
1795.TW has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.